“Maintenance of Bimekizumab Efficacy through 2 Years in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results from Five Phase 3 3b Trials”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s71, https://doi.org/10.25251/skin.6.supp.71.